Abstract
Proof-of-concept for the efficacy of a glucagon-like peptide 1 (GLP-1)-based therapy of patients with type 2 diabetes was provided in 2002 by means of prolonged continuous subcutaneous infusion of native GLP-1. Since then, several long-acting analogues of GLP-1, as well as inhibitors of dipeptidyl peptidase IV, the enzyme that rapidly inactivates endogenous GLP-1, have demonstrated efficacy in long term clinical trials.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Dipeptidyl Peptidase 4 / drug effects*
-
Dipeptidyl Peptidase 4 / metabolism
-
Glucagon / pharmacology
-
Glucagon / therapeutic use*
-
Glucagon-Like Peptide 1
-
Humans
-
Peptide Fragments / pharmacology
-
Peptide Fragments / therapeutic use*
-
Protease Inhibitors / pharmacology
-
Protease Inhibitors / therapeutic use*
-
Protein Precursors / pharmacology
-
Protein Precursors / therapeutic use*
-
United Kingdom
Substances
-
Peptide Fragments
-
Protease Inhibitors
-
Protein Precursors
-
Glucagon-Like Peptide 1
-
Glucagon
-
Dipeptidyl Peptidase 4